Lutetium LU-177 vipivotide tetraxetan
Highest phase reached
Approved
Drug type
Protein
First approval year
2022
- First approval year
- 2022
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Lutetium LU-177 vipivotide tetraxetan
- Molecular weight
- 1,216.07
- Structure (SMILES)
These details could not be displayed.
- pluvicto
- Pluvicto
- 177lu labeled psma 617
- 177lu psma 617
- 177LU-LABELED PSMA-617
- 177lu-psma-617
- 177Lu-PSMA-617
- Administering Lutetium-177-PSMA-617 (PLUVICTO)
- Lutetium (177lu) vipivotide tetraxetan
- lutetium (¹⁷⁷Lu) vipivotide tetraxetan [INN]
- Lutetium (177Lu) vipivotide tetraxetan [MI]
- Lutetium (177Lu) vipivotide tetraxetan [WHO-DD]
- lutetium 177lu vipivotide tetraxetan
- lutetium 177lu vipivotide tetraxetan mi
- lutetium 177lu vipivotide tetraxetan who dd
- lutetium lu 177 vipivotide tetraxetan
- lutetium Lu 177 vipivotide tetraxetan
- Lutetium lu 177 vipivotide tetraxetan
- Lutetium Lu 177 Vipivotide Tetraxetan
- LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN [USAN]
- lutetium lu 177 vipivotide tetraxetan usan
- lutetium lu vipivotide tetraxetan inn
- Lutetium lu-177 vipivotide tetraxetan
- Lutetium Lu-177 vipivotide tetraxetan
- Lutetium Lu-177 Vipivotide Tetraxetan
- pluvicto
- Pluvicto
And 6 more, listed on the interactive page.
- ATC classification codes
- V10XX05
Sources for recorded values
- CAS registry numbers
- 1703749-62-5
- ChEMBL ID
- CHEMBL4594406
- InChIKey
- RSTDSVVLNYFDHY-BGOLSCJMSA-K
- PubChem compound IDs
- 122706785
- RxNorm IDs (RxCUI)
- 2597053
- FDA ingredient codes (UNII)
- G6UF363ECX
- Applicant
- NOVARTIS
- Approval date
- 23 Mar 2022
- Application number
- NDA215833
- Patents
- 5
- Designations
- 4
- Earliest recorded loss of exclusivity
- 18 Sept 2041
- First in class
- Yes
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -tide; -xetan
Administration routes
- Parenteral
- Mechanism
- Glutamate carboxypeptidase II binding agent
- Action type
- BINDING_AGENT
- Target
- Glutamate carboxypeptidase 2
- Protein identifier
- Q04609
- Mechanism
- DNA disrupting agent
- Action type
- DISRUPTING_AGENT
- Target
- DNA
Open Targets mechanisms
- Mechanism
- Glutamate carboxypeptidase II binding agent
- Action type
- BINDING AGENT
- Target
- Glutamate carboxypeptidase 2
- Condition
- Carcinoma, Adenoid Cystic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000231
- Subject identifier
- D003528
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Urogenital Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003863
- Subject identifier
- D014565
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008315
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0021259
- Subject identifier
- D064129
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000231
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000349
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000386
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002120
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002974
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004971
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005005
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005062
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005086
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005089
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005454
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 1
And 14 more, listed on the interactive page.
- NCT03042312
- NCT03042468
- NCT03511664
- NCT03545165
- NCT04343885
- NCT04443062
- NCT04663997
- NCT05079698
- NCT05114746
- NCT05150236
- NCT05340374
- NCT06084338
- NCT06145633
- NCT06216249
- NCT06320067
- NCT06449781
- NCT04430192
- NCT04689828
- NCT04720157
- NCT05162573
- NCT05766371
- NCT06200103
- NCT06288113
- NCT06199453
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 75
- Molecular formula
- C49H68LuN9O16
- Natural product
- No
- 0078-1217
Related records
Trials (47)
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
- 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
- 177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
- 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
- 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
- 177LuPSMA in Renal Cell Carcinoma
- A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
- A Study of 177Lu-PSMA-617 in People With Gliomas
- A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
- Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
- Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
Approved for (2)
In development for (6)
- Adenoid cystic carcinoma Phase 2
- Clear cell renal carcinoma Phase 2
- Metastatic prostate carcinoma Phase 2
- Neoplasm Phase 1
- Prostate adenocarcinoma Phase 3
- Prostate carcinoma Phase 3
Targets (1)
- FOLH1 Glutamate carboxypeptidase II binding agent